CNS Pharmaceutical Inc. (NASDAQ: CNSP) announced its business update, including the recent launch of a pivotal study of its flagship program assessing Berubicin in adult Glioblastoma Multiforme (FB) treatment and expects to commence dosing in Q3 2021.  Berubicin receives Fast Track Designation  The company received Fast track Designation for Berubicin […]